Extended study of gene therapy for inherited blindness
Part of Eyes & vision clinical trials.
This study is a long-term follow-up for people who already received a gene therapy (LX101) for a specific form of inherited blindness called LCA. The goal is to watch how they do over time and check for any lasting effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were already in the earlier LX101 gene therapy study for inherited blindness.
- You and your guardian are willing to sign a consent form and commit to long-term follow-up visits.
- You have no serious eye problems (like advanced glaucoma or cataracts) that could affect the treatment or study results.
- You have no other health issues that make this study unsafe, such as an uncontrolled infection or recent surgery.
- You are not pregnant, breastfeeding, or planning to become pregnant, and if you could become pregnant, you agree to use effective birth control.
- You can stop taking certain medications (like sildenafil for erectile dysfunction or hydroxychloroquine) during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests the safety of putting a gene medicine into the eye for people with vision loss caused by LCA5 gene mutations. It includes a treatment group and a separate group of people who do not receive the gene medicine during the study.
This trial tests an experimental gene therapy (OPGx-RDH12-1001) injected under the retina to treat a rare form of inherited vision loss called LCA caused by RDH12 gene mutations. It aims to see if the treatment is safe and tolerable for people with advanced vision loss.
This Phase 1/2 trial tests the safety and early effectiveness of HG004 (a gene therapy) in people with Leber congenital amaurosis caused by RPE65 gene changes. It aims to see whether treating the eye can improve or stabilize vision-related measures while monitoring side effects.
This trial tests a gene therapy called LX107 for people with vision loss caused by changes in the AIPL1 gene. It aims to see if the treatment is safe and can improve vision.
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
This trial tests a new gene therapy called LX109 for wet age-related macular degeneration (nAMD). It is for patients who still need regular anti-VEGF injections, and the treatment aims to reduce how often you need those injections.
Hear when a new To Evaluate the Scaling Clinical Study of AAV2-RPE65 Gene Therapy Agent (LX101) in Patients With Congenital Amaurosis (LCA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.